The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > ORGANIZATION
ORGANIZATION
- JPMA Not Envisioning Asia-Version EMA at This Point: Chief
April 11, 2019
- Drug Damage Watchdog Nudges Govt, Shionogi to Suspend Xofluza Sales
April 10, 2019
- Vaccine Heavyweight Prods Japan to Expedite Recommendation Process for Immunization Program, Ensure Funding
April 9, 2019
- Patient Groups Press for Emergency Import of Methotrexate amid Tight Supply
April 8, 2019
- Hodanren Calls for Transparency in Kymriah Pricing Process
April 8, 2019
- No More Nonprescription Switches for Lifestyle Disease Drugs, Says JMA Exec
April 5, 2019
- Generic Use Rate at 74.7% in October-December 2018: JGA
March 29, 2019
- BMS Exec Ohura Appointed as CEO of GHIT Fund
March 29, 2019
- JPMA Poised to Continue Pitching Drugs’ Multi-Faceted Values to Politicians: Director General
March 25, 2019
- 2020 Drug Price Revision Is Focus Issue for FPMAJ in FY2019 Plan
March 25, 2019
- FPMAJ Wants Asian Equivalent of EMA, Chairman Stresses Merit of Blanket Approval
March 20, 2019
- EFPIA Official Prods Japan to Limit CEA Application to Financially Impactful Drugs
March 19, 2019
- Kenporen Director Kono: Apply CEA to Reimbursement Decisions Once Credible System Established
March 18, 2019
- Drug Damage Watchdog Opposes Legislation of Conditional Approval System, Calls for Tougher Rules on Ads
March 13, 2019
- Look at Societal Values of Medicines in Pricing: Japan Pharma Industry Chief
March 12, 2019
- Japan Has High Market Access Barriers, Revised PMP Could Stymie Innovation: US Chamber of Commerce Official
March 7, 2019
- Biotech Execs Raise Alarm over Price Maintenance Criteria, CEA Introduction: BIO Asia Confab
March 6, 2019
- Labor Groups Call for Careful Discussions on Cost Effectiveness Assessment
February 19, 2019
- EFPIA Japan Chief Says CEA Selection Criteria Mar Predictability, 5 Billion Yen Sales Threshold “Too Low”
February 19, 2019
- 2019 Is Year to “Get Things Right”: PhRMA Japan Chairman
February 8, 2019
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…